Ruxolitinib versus best available therapy for PV intolerant or resistant to Hydroxycarbamide a randomised trial

被引：0

作者：

Harrison, Claire ^{[1
]}

Nangalia, Jyoti ^{[2
,3
,4
]}

Boucher, Rebecca ^{[5
]}

Jackson, Aimee ^{[5
]}

Yap, Christina ^{[5
,6
]}

O'Sullivan, Jennifer ^{[1
,7
]}

Fox, Sonia ^{[5
]}

Ailts, Isaak ^{[8
]}

Dueck, Amylou ^{[9
]}

Geyer, Holly ^{[8
]}

Mesa, Ruben ^{[10
]}

Dunn, William ^{[4
]}

Nadezhdin, Eugene ^{[3
]}

Curto-Garcia, Natalia

Green, Anna ^{[1
]}

Wilkins, Bridget ^{[1
]}

Coppell, Jason ^{[11
]}

Laurie, John ^{[12
]}

Garg, Mamta ^{[13
]}

Ewing, Joanne ^{[14
]}

Knapper, Steven ^{[15
]}

Crowe, Josephine ^{[16
]}

Chen, Frederick ^{[25
]}

Koutsavlis, Ioannis ^{[17
]}

Godfrey, Anna

Arami, Siamak ^{[18
]}

Drummond, Mark ^{[19
]}

Byrne, Jennifer ^{[20
]}

Clark, Fiona ^{[21
]}

Mead-Harvey, Carolyn

Baxter, Elizabeth ^{[22
]}

McMullin, Mary Frances ^{[23
]}

Mead, Adam ^{[24
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, London, England

[2] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[3] Wellcome Sanger Inst Hinxton, Cambridge, England

[4] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[5] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England

[6] Inst Canc Res, Clin Trials & Stat Unit, London, England

[7] Univ Oxford, Med Res Council MRC, Mol Haematol Unit, MRC Weatherall Inst Mol Med,NIHR,Biomed Res Ctr, Oxford, England

[8] Mayo Clin, Dept Internal Med, Phoenix, AZ USA

[9] Mayo Clin, Dept Quantitat Hlth Sci, Scottsdale, AZ USA

[10] UT Hlth San Antonio MD Anderson, Mays Canc Ctr, San Antonio, TX USA

[11] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England

[12] Western Sussex NHS Fdn Trust, Worthing Hosp, Worthing, England

[13] Univ Hosp Leicester, Leicester, Leics, England

[14] Birmingham Heart England NHS Fdn Trust, Birmingham, W Midlands, England

[15] Cardiff Univ, Sch Med, Cardiff, Wales

[16] Royal United Hosp Bath NHS Trust, Bath, Avon, England

[17] Western Gen Hosp, Edinburgh, Midlothian, Scotland

[18] London North West Healthcare NHS Trust, London, England

[19] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[20] Nottingham Univ Hosp NHS Trust, Nottingham, England

[21] Queen Elizabeth Hosp, Birmingham, W Midlands, England

[22] Cambridge Blood & Stem Cell Biobank NHS BT Cambr, Haematol, Cambridge, England

[23] Queens Univ, Belfast, Antrim, North Ireland

[24] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Canc & Haematol Ctr, Oxford, England

[25] St Bartholomews Hosp, London, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO41

引用

页码：88 / 88

页数：1

共 50 条

[1] Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Harrison, Claire
Nangalia, Jyoti
Boucher, Rebecca H.
Jackson, Aimee
Yap, Christina
O'Sullivan, Jennifer
Fox, Sonia
Ailts, Isaak
Dueck, Amylou C.
Geyer, Holly L.
Mesa, Ruben
Dunn, William
Nadezhdin, Eugene
Curto-Garcia, Natalia
Green, Anna
Wilkins, Bridget
Coppell, Jason
Laurie, John
Garg, Mamta
Ewing, Joanne
Knapper, Steve
Crowe, Josephine
Koutsavlis, Ioannis
Godfrey, Anna L.
Arami, Siamak
Drummond, Mark W.
Byrne, Jennifer
Clark, Fiona J.
Mead-Harvey, Carolyn
Baxter, Joanna E.
McMullin, Mary Frances
Mead, Adam J.
BLOOD, 2022, 140 : 1781 - 1783
[2] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Harrison, Claire N.
Nangalia, Jyoti
Boucher, Rebecca
Jackson, Aimee
Yap, Christina
O'Sullivan, Jennifer
Fox, Sonia
Ailts, Isaak
Dueck, Amylou C.
Geyer, Holly L.
Mesa, Ruben A.
Dunn, William G.
Nadezhdin, Eugene
Curto-Garcia, Natalia
Green, Anna
Wilkins, Bridget
Coppell, Jason
Laurie, John
Garg, Mamta
Ewing, Joanne
Knapper, Steven
Crowe, Josephine
Chen, Frederick
Koutsavlis, Ioannis
Godfrey, Anna
Arami, Siamak
Drummond, Mark
Byrne, Jennifer
Clark, Fiona
Mead-Harvey, Carolyn
Baxter, Elizabeth Joanna
McMullin, Mary Frances
Mead, Adam J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3534 - +
[3] Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison, Claire N.
Mead, Adam J.
Panchal, Anesh
Fox, Sonia
Yap, Christina
Gbandi, Emmanouela
Houlton, Aimee
Alimam, Samah
Ewing, Joanne
Wood, Marion
Chen, Frederick
Coppell, Jason
Panoskaltsis, Nicki
Knapper, Steven
Ali, Sahra
Hamblin, Angela
Scherber, Robyn
Dueck, Amylou C.
Cross, Nicholas C. P.
Mesa, Ruben
McMullin, Mary Frances
BLOOD, 2017, 130 (17) : 1889 - 1897
[4] RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD RANDOMIZED TRIAL
Harrison, C.
Mead, A.
Panchal, A.
Fox, S.
Yap, C.
Houlton, A.
Aliman, S.
Wood, M.
Chen, F.
Coppell, J.
Panoskaltsis, N.
Scherber, R.
Geyer, H.
Dueck, A.
Mesa, R.
McMullin, M. F.
HAEMATOLOGICA, 2016, 101 : 97 - 97
[5] Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Harrison, Claire N.
Griesshammer, Martin
Miller, Carole
Masszi, Tamas
Passamonti, Francesco
Zachee, Pierre
Durrant, Simon
Pane, Fabrizio
Guglielmelli, Paola
Verstovsek, Srdan
Jones, Mark M.
Hunter, Deborah S.
Sun, William
Li, Jingjin
Khan, Mahmudul
Habr, Dany
Kiladjian, Jean-Jacques
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 279 - 284
[6] RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with bydroxyurea (HU)- resistant/intolerant polycytheinia vera (PV) versus best available therapy (BAT).
Passamonti, Francesco
Saydam, Guray
Lim, Liberata
Khan, Mahmudul H.
Mounedji, Nadjat
Griasshammer, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] COST-UTILITY ANALYSIS OF RUXOLITINIB VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF HYDROXYUREA RESISTANT/INTOLERANT POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY IN THE UNITED STATES
Hong, S.
Veenstra, D. L.
VALUE IN HEALTH, 2020, 23 : S50 - S50
[8] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Harrison, Claire
Kiladjian, Jean-Jacques
Al-Ali, Haifa Kathrin
Gisslinger, Heinz
Waltzman, Roger
Stalbovskaya, Viktoriya
McQuitty, Mari
Hunter, Deborah S.
Levy, Richard
Knoops, Laurent
Cervantes, Francisco
Vannucchi, Alessandro M.
Barbui, Tiziano
Barosi, Giovanni
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09): : 787 - 798
[9] The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
O'Sullivan, Jennifer M.
Hamblin, Angela
Yap, Christina
Fox, Sonia
Boucher, Rebecca
Panchal, Anesh
Alimam, Samah
Dreau, Helene
Howard, Kieran
Ware, Pauline
Cross, Nicholas C. P.
McMullin, Mary Frances
Harrison, Claire N.
Mead, Adam J.
BLOOD, 2019, 134 (23) : 2107 - 2111
[10] Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Harrison, Claire N.
Vannucchi, Alessandro M.
Platzbecker, Uwe
Cervantes, Francisco
Gupta, Vikas
Lavie, David
Passamonti, Francesco
Winton, Elliott F.
Dong, Hua
Kawashima, Jun
Maltzman, Julia D.
Kiladjian, Jean-Jacques
Verstovsek, Srdan
LANCET HAEMATOLOGY, 2018, 5 (02): : E73 - E81

← 1 2 3 4 5 →